Last update: Dec. 10, 2019
Minimal risk for breastfeeding and infant.
Histamine H2 receptor antagonist that inhibits gastric acid secretion.
Indicated in the treatment of gastric and duodenal ulcer and peptic esophagitis.
Oral or intravenous administration in one or two daily doses.
It is concentrated in breastmilk and is excreted in moderate quantities (Kearns 1985, Riley 1982 cited in Bennet 1996 p329), but is 5 to 25 times lower than the dose used in newborns and infants (2-4 mg/kg/day).
No side effects have been observed in infants whose mothers were taking ranitidine (Kearns 1985).
It is commonly used in Pediatrics, even in premature newborns.
Other anti H2s from the same family are excreted less in breastmilk and may be preferred (Hagemann 1998).
Several medical assocoations, experts and expert consensus consider its use to be safe during breastfeeding (Hale 2019, Briggs 2017, Rowe 2013, Mahadevan 2006, Richter 2005, Nice 2000).
It can produce hyperprolactinemia (Petit 2003).
*** Since 10/2019, oral preparations (not intravenous) of Ranitidine have been withdrawn from the market in several countries because some of them have detected contamination with Nitrosamine (N-Nitrosodimethylamine, NDMA) a carcinogenic product. It is advised, until the situation has cleared up, to switch to omeprazole or famotidine (AEMPS 2019).
Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine from United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM